Adherence to adjuvant immunotherapy and TKIs in resected in NSCLC

Recent developments in the treatment of NSCLCПодробнее

How can adherence to treatment protocols for resectable NSCLC be improved?Подробнее

EGFR TKIs in the Adjuvant Setting in NSCLCПодробнее

Adjuvant Versus Neoadjuvant Therapy in NSCLCПодробнее

Outcomes and pCR after chemo-immunotherapy in resectable NSCLCПодробнее

Current Status of Adjuvant Therapy for NSCLCПодробнее

Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trialПодробнее

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Immunotherapy as combination and neoadjuvant therapies in NSCLCПодробнее

IMpower010: OS results of atezolizumab vs best supportive care in resected NSCLCПодробнее

Has Immunotherapy Brought Us to an Inflection Point in the Management of Stage I-III NSCLC?Подробнее

S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant TherapyПодробнее

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLCПодробнее

EGFR TKIs as Adjuvant Therapy in NSCLCПодробнее

Surgical perspective on neoadjuvant IO for resectable stage III NSCLCПодробнее

For NSCLC Neoadjuvant Adjuvant or BothПодробнее

Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLCПодробнее

ALINA: evaluating the safety of adjuvant alectinib for ALK+ NSCLCПодробнее

Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLCПодробнее